IO Biotech Shares Surge on Renewed Regulatory Prospects

IO Biotech witnessed a dramatic single-day surge of more than 25% in its share price yesterday. This powerful rally was fueled by the company’s latest quarterly financial report and significant progress in the regulatory pathway for its cancer vaccine candidate, Cylembio.

A pivotal development driving investor sentiment is the scheduled meeting with the U.S. Food and Drug Administration (FDA) in December 2025. This meeting is set to finalize the design for a new Phase 3 clinical trial for Cylembio. The event represents a critical step forward, coming just months after the FDA had previously advised against a regulatory filing for the drug, a move that had triggered a significant stock decline and Read more...